fluoxetine has been researched along with Liver Steatosis in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine is a first-line selective serotonin reuptake inhibitor widely applied for the treatment of depression; however, it induces abnormal hepatic lipid metabolism." | 1.62 | Downregulation of glucose-6-phosphatase expression contributes to fluoxetine-induced hepatic steatosis. ( Bai, M; Chen, Y; Gu, Y; Jiang, H; Li, P; Lu, S; Ma, Z; Yang, X; Zhou, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, S | 1 |
| Ma, Z | 1 |
| Gu, Y | 1 |
| Li, P | 1 |
| Chen, Y | 1 |
| Bai, M | 1 |
| Zhou, H | 1 |
| Yang, X | 1 |
| Jiang, H | 1 |
1 other study available for fluoxetine and Liver Steatosis
| Article | Year |
|---|---|
Downregulation of glucose-6-phosphatase expression contributes to fluoxetine-induced hepatic steatosis.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Fatty Liver; Fluoxetine; Glucose-6-Phosp | 2021 |